- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: AIDS-Related Lymphoma - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
- The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy.
- Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
- Natural killer-like T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus.
- Primary renal non-Hodgkin's lymphoma with inferior vena cava involvement: report of one case in HIV-infected patient.
- Human herpesvirus 8-associated primary effusion lymphoma in HIV--patients: a clinicopidemiologic variant resembling classic Kaposi's
- AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment.
- Lymphoma of the head and neck and acquired immunodeficiency syndrome: clinical investigation and immunohistological study.
- Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.
- [Systemic HIV-non-Hodgkin lymphoma in the era of HAART. Natural history]
- Anti-cancer agents. Lymphoma in the age of HAART.
- Anti-viral therapy for lymphoma.
- Anti-cancer agents. Hydroxyurea as anti-viral therapy for brain lymphoma.
- Predicting lymphoma with soluble CD27.
Table of Contents
1
UI - 11874639
AU - Welch K; Morse A; Adult Spectrum of Disease Project in New Orleans
TI -
The clinical profile of end-stage AIDS in the era of highly active
antiretroviral therapy.
SO - AIDS Patient Care STDS 2002 Feb;16(2):75-81
AD - Louisiana Office of Public Health, Centers for Disease Control and
Prevention, New Orleans, Louisiana, USA. kwelch56@hotmail.com
The purpose of this study was to describe the clinical profile of
end-stage acquired immune deficiency syndrome (AIDS) since the advent of
highly active antiretroviral therapy (HAART). A cross-sectional
examination of human immunodeficiency virus (HIV)-infected patients who
attended a public HIV outpatient clinic and died between 1996 and 2001
was conducted (n = 669). All clinical and demographic data were
collected from the Centers for Disease Control (CDC) Adult Spectrum of
Disease database. The prevalence of first-time acquisition of
AIDS-defining conditions 12 months before death were evaluated. The
prevalence of renal disease, hepatic disease and substance use were also
evaluated. The majority of the patients were 35 years old or older,
male, African American and HAART-experienced. The six AIDS-defining
conditions with the highest percentages of first-time acquisition in the
last 12 months of life were HIV dementia (91.8%), progressive multifocal
leukoencephalopathy (PML) (91.7%), wasting (90.9%), Mycobacterium avium
complex infection (MAC) (80.0%), lymphoma (78.6%), and cytomegalovirus
infection (CMV) (78.1%). Forty-four percent of the patients were
diagnosed with at least one of these six conditions 12 months before
death. More than one third of the patients had renal or hepatic failure,
injecting drug use (IDU) as the HIV risk factor, and history of
substance use. AIDS-defining conditions continue to have an impact on
mortality, especially the neurologic conditions and wasting. However,
other conditions, such as renal and hepatic disease, are becoming
important causes of mortality because the HIV-infected population now
includes more drug users, and HIV-infected patients are surviving for
longer periods. These results should help clinicians better time the
discussion of end-stage options and improve the patient's quality of
life.
2
UI - 11895917
AU - Alas S; Ng CP; Bonavida B
TI -
Rituximab modifies the cisplatin-mitochondrial signaling pathway,
resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
SO - Clin Cancer Res 2002 Mar;8(3):836-45
AD - Department of Microbiology, Immunology, and Molecular Genetics,
University of California Los Angeles School of Medicine and Jonsson
Comprehensive Cancer Center, University of California, Los Angeles,
California 90095, USA.
PURPOSE: Rituximab (chimeric anti-CD20) can reverse the
cisplatin-resistant phenotype of AIDS-related non-Hodgkin's lymphoma
cell lines and results in cisplatin-mediated apoptosis. The mechanism by
which apoptosis is achieved by the combination treatment was examined.
EXPERIMENTAL DESIGN: The AIDS-related lymphoma (ARL) cell line 2F7 was
treated with rituximab, cisplatin, and a combination of the two and
analyzed by Western blot analyses for signaling proteins involved in the
death receptor-mediated and mitochondrial pathways. RESULTS: Rituximab
selectively inhibited the expression of Bcl-2 in the ARL cells. However,
other proteins analyzed [namely, Apaf-1, Bax, Bid, caspase-3, caspase-8,
caspase-9, X-linked inhibitor of apoptosis protein (XIAP), cellular
inhibitor of apoptosis protein (cIAP)-1, cIAP-2, cytochrome c, Fas, Fas
ligand, FLIP, p53, and poly(ADP-ribose) polymerase] were not affected by
either rituximab or cisplatin. Treatment with cisplatin induced the
generation of mitochondrial reactive oxygen species, specifically
intracellular peroxides. Furthermore, cisplatin alone was unable to
induce the mitochondrial apoptotic events; however, the
rituximab-cisplatin combination was able to synergistically induce
significant apoptosis and mitochondria-mediated apoptotic events
[mitochondrial membrane depolarization (DeltaPsi(m)), cytochrome c
release from mitochondria, and caspase-3 and -9 activation]. The
combination treatment facilitated the down-regulation of Bcl-2 by
rituximab at an early time point. Decreased expression of additional
proteins (Apaf-1, cIAP-1, cIAP-2, and XIAP) paralleled apoptosis
detected at 24 h. CONCLUSIONS: These findings show that the selective
down-regulation of Bcl-2 by rituximab leading to apoptosis in ARL cells
by cisplatin is through the mitochondria-dependent caspase pathway.
3
UI - 12033970
AU - Cornfield DB; Papiez JS; Lynch JT; Rimsza LM
TI -
Natural killer-like T-cell lymphoma of the parotid in a patient infected
with human immunodeficiency virus.
SO - Arch Pathol Lab Med 2002 Jun;126(6):738-41
AD - Department of Pathology, University of Florida College of Medicine,
Gainesville, USA. cornf1@dca.net
A 42-year-old man with acquired immunodeficiency syndrome developed a
mass of the right parotid gland and multiple hepatic masses.
Hematoxylin-eosin-stained sections of the parotid lesion showed a
diffuse infiltrate of large mononuclear cells with vesicular nuclei and
prominent nucleoli, consistent with a non-Hodgkin lymphoma.
Immunohistochemical stains demonstrated expression of the T-cell markers
CD3 and UCHL-1, as well as latent membrane protein 1 and T-cell
intracellular antigen 1. Flow cytometry showed surface expression of
CD2, CD3, CD7 (dim), CD8, and CD56. CD5 was not expressed. Molecular
evaluation by polymerase chain reaction demonstrated monoclonal
rearrangement of the T-cell receptor gamma gene. Epstein-Barr virus
early RNA and human immunodeficiency virus RNA were demonstrated by in
situ hybridization. To our knowledge, this is the first reported case of
T-cell lymphoma of the parotid in a patient infected with human
immunodeficiency virus. After 2 separate chemotherapy regimens, the
patient achieved clinical remission for 1(1/2) years; he then developed
progressive pulmonary lesions and died.
4
UI - 11976627
AU - Busi Rizzi E; Schinina V; Cristofaro M; Bellussi A; Alba L; Bibbolino C
TI -
Primary renal non-Hodgkin's lymphoma with inferior vena cava
involvement: report of one case in HIV-infected patient.
SO - Radiol Med (Torino) 2002 Mar;103(3):279-82
AD - Department of Radiology, National Institute for Infectious Diseases L.
Spallanzani, Rome, Italy.
5
UI - 11940475
AU - Ascoli V; Lo Coco F; Torelli G; Vallisa D; Cavanna L; Bergonzi C; Luppi
TI -
M
Human herpesvirus 8-associated primary effusion lymphoma in
HIV--patients: a clinicopidemiologic variant resembling classic Kaposi's
sarcoma.
SO - Haematologica 2002 Apr;87(4):339-43
6
UI - 12055673
AU - Carbone A
TI -
AIDS-related non-Hodgkin's lymphomas: from pathology and molecular
pathogenesis to treatment.
SO - Hum Pathol 2002 Apr;33(4):392-404
AD - Division of Pathology and Scientific Direction, Centro di Riferimento
Oncologico-IRCCS, National Cancer Institute, Aviano, Italy.
In the highly active antiretroviral therapy (HAART) era, AIDS-related
non-Hodgkin's lymphomas (AIDS-NHL) and their treatment still represent
an open issue, because HAART may not be sufficient to prevent the
development of NHL. The present spectrum of AIDS-NHL includes systemic
lymphomas, primary central nervous system lymphomas, and 2 rare
entities, primary effusion lymphomas (PEL) and plasmablastic lymphomas
of the oral cavity. The vast majority of systemic AIDS-NHL belongs to 3
high-grade B-cell lymphomas: Burkitt's lymphoma (BL), immunoblastic
lymphoma (IBL), and large-cell lymphoma (LCL). The pathologic
heterogeneity of AIDS-NHL is correlated with the heterogeneity of the
molecular lesions associated with these lymphomas. The molecular lesions
associated with AIDS-BL involve activation of c-MYC inactivation of p53,
and infection by Epstein-Barr virus (EBV). EBV infection occurs in 40%
of LCL cases and in 90% of IBL cases. Rearrangements of BCL-6 are
detected in 20% of AIDS-LCL cases. In the presence of EBV infection,
BCL-6 expressing AIDS-LCL fails to express the latent membrane protein 1
(LMP1) antigen. Conversely, AIDS-IBL are characterized by absent BCL-6
expression, absence of BCL-6 rearrangements, and frequent expression of
LMP1. Consistently, the molecular pathways of viral infection and
lesions of cancer-related genes associated with AIDS-NHL vary
substantially in different clinicopathologic categories of the disease.
The marked degree of biologic heterogeneity of AIDS-NHL is highlighted
by their histogenetic differences, because AIDS-NHL are related to
distinct B cell subsets (ie, germinal center [GC] or post-GC B cells).
The phenotypic pattern of AIDS-BL and systemic AIDS-LCL closely reflects
B cells residing in the GC, namely centroblasts and centrocytes.
Conversely, the phenotype of AIDS-IBL, either systemic or localized
primarily to the central nervous system, and AIDS-PEL reflects post-GC B
cells in all cases. New information on the molecular and virologic
pathogenesis of AIDS-NHL may serve as a point of attack for
pathogenic-driven therapies. Moreover, a greater knowledge of other
biologic features of these tumors may help investigators identify new
potential targets for "intelligent" therapies. Copyright 2002, Elsevier
Science (USA). All rights reserved.
7
UI - 7715397
AU - Finn DG
TI -
Lymphoma of the head and neck and acquired immunodeficiency syndrome:
clinical investigation and immunohistological study.
SO - Laryngoscope 1995 Apr;105(4 Pt 2 Suppl 68):1-18
AD - Department of Otolaryngology--Head and Neck Surgery, New York Eye and
Ear Infirmary/New York Medical College, USA.
The epidemic of acquired immunodeficiency syndrome (AIDS) has made an
enormous impact in the practice of medicine within the past decade. Of
the many associated problems, the increasing frequency of human
immunodeficiency virus (HIV)-related malignancies, particularly
lymphoma, has been both a fascinating area of study and a most difficult
clinical condition to manage. This study investigates lymphoma of the
head and neck with clinical studies, as well as immunohistochemical
assessments from individual patients. Lymphomas of the head and neck, as
they present to the otolaryngologist, can present difficult and
challenging diagnostic and therapeutic dilemmas. It is well-known that a
significant number of acquired immunodeficiency patients present
initially with symptoms related to the otolaryngology field; it was also
found that a certain number of lymphomas in the head and neck in HIV+
patients are the initial presentation. In addition, the associated
disorders, such as related infections and synchronous additional
neoplasms, are described. Also presented are recommendations for
diagnosis and work-up of these conditions, based on the experience. In
addition, the study of lymphoma as a neoplasm from the molecular biology
viewpoint and its course in the immunodeficient state have been
important areas of study in an effort to dissect the progression to
oncogenesis. The rapidly expanding literature base in this area is
discussed.
8
UI - 12102166
AU - Baiocchi OC; Colleoni GW; Navajas EV; Duarte LC; Alves AC; Andrade AL;
TI -
Kerbauy J; Oliveira JS
Impact of highly active antiretroviral therapy in the treatment of
HIV-infected patients with systemic non-Hodgkin's lymphoma.
SO - Acta Oncol 2002;41(2):192-6
AD - Hematology and Transfusion Service, Universidade Federal de Sao Paulo,
Brazil.
Twenty cases of systemic non-Hodgkin's lymphoma (NHL) in HIV-infected
patients were reviewed over a 10-year-period, divided into Group A,
including 13 NHL cases treated before the highly active antiretroviral
therapy (HAART) era, and Group B, including 7 patients who received
HAART. A Kaplan-Meier survival curve was performed and log-rank was
applied to assess statistical differences between the groups. In group
A, the median CD4 count was 36 cells/mm3. No complete remission was
found. In group B, the median CD4 count was 137 cells/mm3. Four patients
(57.0%) are still alive and in complete remission. Group A had a median
survival of 5 months and group B 31 months (p = 0.0032). Our results are
in agreement with recent reports in that a higher CD4 count and better
immune status achieved with HAART is predictive of a better outcome. We
found that HAART in combination with chemotherapy improves overall
survival of NHL patients without increasing adverse effects.
9
UI - 11765662
AU - Juzbasic S; Spina M; Vaccher E; Tirelli U
TI -
[Systemic HIV-non-Hodgkin lymphoma in the era of HAART. Natural history]
SO - Recenti Prog Med 2001 Nov;92(11):676-89
AD - Divisione di Oncologia Medica A, Istituto Nazionale Tumori, Centro di
Riferimento Oncologico, Aviano.
In the era of highly active antiretroviral therapy (HAART), systemic
non-Hodgkin lymphoma (NHL) represented the most frequent cancer
associated to HIV infection. In contrast to Kaposi's sarcoma and primary
central nervous system lymphoma (PCNSL) which incidence have been
declining after introduction of HAART, systemic NHL-HIV has relatively
stable remained. Systemic HIV related NHL are markedly heterogeneous
both histologically and clinically and this clinicophatological
heterogenity reflects variability in the molecular lesions associated to
these lymphomas and immunological status of these patients. The
introduction of HAART has substantially modified the approach to HIV
related lymphomas. The results of recent monoinstitutional study of
Aviano Cancer's Institute on 235 patients have suggested that HAART
would otherwise allow a long life expectancy with longer disease free
survival and overall survival. In fact the reduced of morbidity of AIDS
patients bought by HAART justified the use of aggressive antineoplastic
therapies.
10
UI - 12132461
AU - Anonymous
TI -
Anti-cancer agents. Lymphoma in the age of HAART.
SO - Treatmentupdate 2000 Sep;12(6):4-5
11
UI - 12132462
AU - Anonymous
TI -
Anti-viral therapy for lymphoma.
SO - Treatmentupdate 2000 Sep;12(6):5-6
12
UI - 12132463
AU - Anonymous
TI -
Anti-cancer agents. Hydroxyurea as anti-viral therapy for brain
lymphoma.
SO - Treatmentupdate 2000 Sep;12(6):6
13
UI - 12125632
AU - Anonymous
TI -
Predicting lymphoma with soluble CD27.
SO - Treatmentupdate 2000 Jan;11(10):10
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
